The aim of the present paper was to review recent developments in the management of patients with acute kidney injury or chronic kidney disease occurring secondary to either cancer itself or its therapy, with a focus on infiltration of the renal parenchyma, myeloma, tumor lysis syndrome, glomerular disease, thrombotic microangiopathy, chemotherapy-associated thrombotic microangiopathy, biphosphonate-induced renal diseases, acute kidney injury, and chronic kidney disease after hematopoietic cell transplantation. Further studies are awaited because a better knowledge of renal complications, which frequently occur in patients with oncohematologic diseases, would be conducive to making an early diagnosis and providing prompt therapy.
KapoorM, ChanGZ. Malignancy and renal disease. Crit Care Clin. 2001; 17:571–598.
2.
da SilvaJ, MeslerD. Acute renal failure as a result of malignancy. In: MolitorisB, FinnW, eds.Acute Renal Failure: A Companion to Brenner and Rector's The Kidney. Indianapolis, IN: Harcourt; 2001:312–321.
3.
BladeJ, Fernandez-LlamaP, BoschF, . Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med. 1998; 158:1889–1893.
4.
CogginsCH. Renal failure in lymphoma. Kidney Int. 1980; 17:847–855.
5.
RichmondJ, ShermanRS, DiamondHD, . Renal lesions associated with malignant lymphomas. Am J Med. 1962; 32:184–207.
6.
WagleDG, MooreRH, MurphyGP. Secondary carcinomas of the kidney. J Urol. 1975; 114:30–32.
7.
ManningEC, BelenkoMI, FrauenhofferEE, . Acute renal failure secondary to solid tumor renal metastases: case report and review of the literature. Am J Kidney Dis. 1996; 27:284–291.
8.
Eleutherakis-PapaiakovouV, BamiasA, GikaD, . Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma. 2007; 48:337–341.
9.
BatumanV, VerroustPJ, NavarGL, . Myeloma light chain are ligands for cubilin (gp280). Am J Physiol. 1998; 275:F246–254.
10.
SantostefanoM, ZanchelliF, ZaccariaA, . The ultrastructural basis of renal pathology in monoclonal gammopathies. J Nephrol. 2005; 18:659–675.
11.
YingWZ, SandersPW. Mapping the binding domain of immunoglobulin light chains for Tamm-Horsfall protein. Am J Pathol. 2001; 158:1859–1866.
12.
RoncoP, PlaisierE, MougenotB, . Immunoglobulin light (heavy)-chain deposition disease: from molecular medicine to pathophysiology-driven therapy. Clin J Am Soc Nephrol. 2006; 1:1342–1350.
13.
MaCX, LacyMQ, RompalaJF, . Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma. Blood. 2004; 104:40–42.
14.
KeelingJ, HerreraGA. The mesangium as target for glomerulopathic light and heavy chains: pathogenic considerations in light and heavy chain-mediated glomerular damage. Contrib Nephrol. 2007; 153:116–134.
15.
ContéLG, FigueroaMG, LoisVV, . Prognostic value of the new international staging system in multiple myeloma. Comparison with Durie-Salmon staging system. Rev Med Chil. 2008; 136:7–12.
16.
MayoMM, JohnsGS. Serum free light chains in the diagnosis and monitoring of patients with plasma cell dyscrasias. Contrib Nephrol. 2007; 153:44–65.
17.
ZucchelliP, PasqualiS, CagnoliL, . Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int. 1988; 33:1175–1180.
18.
ClarkWF, StewartAK, RockGA, . Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med. 2005; 143:777–784.
19.
HutchisonCA, CockwellP, ReidS, . Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol. 2007; 18:886–895.
20.
HutchisonCA, CookM, BasuS, . Combined chemotherapy and high cut-off hemodialysis improve outcomes in multiple myeloma patients with severe renal failure [abstract]. Blood. 2007; 110:3610.
21.
TosiP, ZamagniE, CelliniC, . Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Eur J Haematol. 2004; 73:98–103.
22.
Pineda-RomanM, TricotG. High dose therapy in patients with plasma cell dyscrasias and renal dysfunction. Contrib Nephrol. 2007; 153:182–194.
23.
NiesvizkyR, NaibT, CristosPJ, . Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy. Br J Haematol. 2007; 138:640–643.
24.
NiesvizkyR, JayabalanDS, ChristosPJ, . BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naïve symptomatic multiple myeloma. Blood. 2008; 111:1101–1109.
25.
San-MiguelJF, RichardsonPG, SonneveldP, . Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia. 2008; 22:842–849.
26.
LudwigH, DrachJ, GrafH, . Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica. 2007; 92:1411–1414.
27.
CarlsonK. Melphalan 200 mg/m2 with blood stem cell support as first-line myeloma therapy: impact of glomerular filtration rate on engraftment, transplantation-related toxicity and survival. Bone Marrow Transplant. 2005; 35:985–990.
28.
GertzMA, LacyMQ, DispenzieriA, . Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplant. 2007; 39:605–611.
DavidsonMB, ThakkarS, HixJK, . Pathophysiology, clinical consequences and treatment of tumor lysis syndrome. Am J Med. 2004; 116:546–554.
31.
CongerJD. Acute uric acid nephropathy. Med Clin North Am. 1990; 74:859–871.
32.
JohnsonRJ, KivlighnSD, KimYG, . Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease. Am J Kidney Dis. 1999; 33:225–234.
33.
JeromeKR, CoreyL. The danger within. N Engl J Med. 2004; 350:411–412.
34.
BolesJM, DutelJL, BriereJ, . Acute renal failure caused by extreme hyperphosphatemia after chemotherapy of an acute lymphoblastic leukemia. Cancer. 1984; 53:2425–2429.
35.
ZagerRA. Hyperphosphatemia: a factor that provokes severe experimental acute renal failure. J Lab Clin Med. 1982; 100:230–239.
EagenJW. Glomerulopathies of neoplasia. Kidney Int. 1977; 11:297–303.
47.
PankhurstT, SavageCO, GordonC, . Malignancy is increased in ANCA-associated vasculitis. Rheumatology (Oxford). 2004; 43:1532–1535.
48.
EdgarJD, RooneyDP, McNameeP, . An association between ANCA positive renal disease and malignancy. Clin Nephrol. 1993; 40:22–25.
49.
KnightA, AsklingJ, EkbomA. Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis. Int J Cancer. 2002; 100:82–85.
50.
MoakeJL. Thrombotic microangiopathies. N Engl J Med. 2002; 347:589–600.
51.
GeorgeJN, SelbyGB. Thrombotic microangiopathy after allogenic bone marrow transplantation: a pathologic abnormality associated with diverse clinical syndromes. Bone Marrow Transplant. 2004; 33:1073–1074.
52.
HalevyD, RadhakrishnanJ, MarkowitzG, . Thrombotic microangiopathies. Crit Care Clin. 2002; 18:309–2, vi.
FungMC, StornioloAM, NguyenB, . A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer. 1999; 85:2023–2032.
60.
FlombaumCD, MouradianJA, CasperES, . Thrombotic microangiopathy as a complication of long-term therapy with gemcitabine. Am J Kidney Dis. 1999; 33:555–562.
61.
ConteP, GuarneriV. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist. 2004; 9(suppl 4):28–37.
62.
ShreedharaM, FenvesAZ, StoneMJ. Reversibility of pamidronate-associated glomerulosclerosis. Proc (Bayl Univ Med Cent). 2007; 20:249–253.
63.
DesikanR, VekslerY, RazaS. Nephrotic proteinuria associated with high dose pamidronate in multiple myeloma. Br J Haematol. 2002; 119:496–499.
64.
BraunJP, RicoAG, BenardP. Urinary gamma-glutamyl transferase in renal toxicology of the rat. Basis of its use and significance in acute mercurial nephritis. Toxicology. 1978; 11:73–82.
65.
LaurinaciciusA, HurwitzS, RennkeHG. Collapsing glomerulopathy in HIV and non-HIV patients: a clinicopathological and follow-up study. Kidney Int. 1999; 56:2203–2213.
YatesAJP, GrayRES, UrwinGH. Intravenous clodronate in the treatment and retreatment of Paget's disease of bone. Lancet. 1985; I:1474–1477.
69.
DumonJC, MagritteA, BodyJJ. Efficacy and safety of the bisphosphanate tiludronate for the treatment of tumor associated hypocalcaemia. Bone Miner. 1991; 15:257–266.
70.
MarkowitzGS, AppelGB, FinePL, . Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol. 2001; 12:1164–1172.
71.
KuninM, KopolovicJ, AvigdorA, . Collapsing glomerulopathy induced by long-term treatment with standard-dose pamidronate in a myeloma patient. Nephrol Dial Transplant. 2004; 19:723–726.
72.
D'AgatiV, SuhJI, CarboneL, . Pathology of HIV-associated nephropathy: a detailed morphologic and comparative study. Kidney Int. 1989; 35:1358–1370.
73.
MarkowitzGS, FinePL, StackJI, . Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int. 2003; 64:281–289.
74.
BanerjeeD, AsifA, StrikerL, . Short-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity. Am J Kidney Dis. 2003; 41:E18.
RosenLS, GordonD, KaminskiM. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001; 7:377–387.
77.
RosenLS, GordonD, KaminskiM. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003; 98:1735–1744.
78.
SaadF, GleasonDM, MurrayR. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002; 94:1458–1468.
79.
RosenLS, GordonD, TchekmedyianS. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003; 21:3150–3157.
80.
RosenLS, GordonD, TchekmedyianNS. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non-small cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer. 2004; 100:2613–2621.
81.
ChangJT, GreenL, BeitzJ. Renal failure with the use of zoledronic acid. N Engl J Med. 2003; 349(17):1676–1679.
AliSM, EstevaFJ, HortobagyiG. Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol. 2001; 19:3434–3437.
85.
GuarneriV, DonatiS, NicoliniM. Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 years. Oncologist. 2005; 10:842–848.
86.
GuarneriV, DonatiS, NicoliniM, . Renal safety of zoledronic acid in patients with bone metastases from breast cancer or other tumors treated with intravenous bisphosphonates for up to ten years. Ann Oncol. 2004; 15:811.
87.
RosenLS, GordonD, TchekmedyanS. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial. J Clin Oncol. 2003; 21:3150–3157.
88.
JacksonGM. Renal safety of ibandronate. Oncologist. 2005; 10(suppl 1):14–18.
89.
HillnerBE, IngleJN, ChlebowskiRT. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2004; 22:1351.
90.
SafirsteinRL. Renal diseases induced by antineoplastic agents. In: SchrierRW, ed.Diseases of the Kidney and Urinary Tract. Philadelphia, PA: Lippincott; 2001:1175–1188.
91.
DarmonM, CiroldiM, ThieryG, . Clinical review: specific aspects of acute renal failure in cancer patients. Crit Care. 2007; 10(2):211.
92.
LangerakAD, DreisbachLP. Chemotherapy Regimens and Cancer Care. Georgetown, TX: Landes Bioscience; 2001.
93.
CurranWJ. New chemotherapeutic agents: update of major chemoradiation trials in solid tumors. Oncology. 2002; 63(suppl 2):29–38.
94.
Gonzales-VitaleJC, HayesDM, CvitkovicE, . The renal pathology in clinical trials of cis-platinum (II) diamminedichloride. Cancer. 1977; 39:1362–1371.
95.
AliBH, Al-MoundhriM, TageldinM, . Ontogenic aspects of cisplatin-induced nephrotoxicity in rats. Food Chem Toxicol. 2008; 46:3355–3359.
96.
BarabasK, MilnerR, LurieD, . Cisplatin: a review of toxicities and therapeutic applications. Vet Comp Oncol. 2008; 6:1–18.
97.
HaniganMH, GallagherBC, TaylorPTJr., . Inhibition of gamma-glutamyl transpeptidase activity by acivicin in vivo protects the kidney from cisplatin-induced toxicity. Cancer Res. 1994; 54:5925–5929.
98.
HaniganMH, GallagherBC, TownsendDM, . Gamma-glutamyl transpeptidase accelerates tumor growth and increases the resistance of tumors to cisplatin in vivo. Carcinogenesis. 1999; 520:553–559.
99.
HaniganMH, LykissaED, TownsendDM, . Gamma-glutamyl transpeptidase-deficient mice are resistant to the nephrotoxicity of cisplatin. Am J Pathol. 2001; 159:1889–1894.
100.
WainfordRD, WeaverRJ, StewartKN, . Cisplatin nephrotoxicity is mediated by gamma glutamyltranspeptidase, not via a C-S lyase governed biotransformation pathway. Toxicology. 2008; 249:184–193.
101.
FrancescatoHD, CostaRS, da SilvaCG, . Treatment with a p38 MAPK inhibitor attenuates cisplatin nephrotoxicity starting after the beginning of renal damage. Life Sci. 2009; 84:590–597.
Launay-VacherV, ReyJ-B, Isnard-BagnisC, . Prevention of cisplatin nephrotoxixity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol. 2008; 61:903–909.
104.
HolsteinSA, StokesJB, HohlRJ. Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia. Leuk Res. 2009; 33:344–347.
105.
FrançoisH, CoppoP, HaymanJP, . Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss. Am J Kidney Dis. 2008; 51:298–301.
106.
GibbonsJ, EgorinMJ, RamanathanRK, . Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol. 2008; 4:570–576.
107.
IzzedineH, RixeO, BillemontB, . Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am J Kidney Dis. 2007; 50:203–218.
108.
HalimiJM, AziziM, BobrieG, . Vascular and renal effects of anti-angiogenic therapy. Nephrol Ther. 2008; 4:602–615.
109.
GurevichF, PerazellaMA. Renal effects of anti-angiogenesis therapy: update for the internist. Am J Med. 2009; 122:322–328.
110.
StokesMB, ErazoMC, D'AgatiVD. Glomerular disease related to anti-VEGF therapy. Kidney Int. 2008; 74:1487–1491.
111.
VereminaJA, KowalewskaJJ, HochsterH, . VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008; 11:1129–1136.
112.
ZagerRA, O'QuigleyJ, ZagerBK, . Acute renal failure following bone marrow transplantation: a retrospective study of 272 patients. Am J Kidney Dis. 1988; 13:210–216.
113.
HahnT, RondeauC, ShaukatA, . Acute renal failure requiring dialysis after allogenic blood and marrow transplantation identifies very poor prognosis patients. Bone Marrow Transplant. 2003; 32:405–410.
NoelC, HazzanM, Noel-WalterMP, . Renal failure and bone marrow transplantation. Nephrol Dial Transplant. 1998; 13:2464–2466.
116.
ZagerRA. Acute renal failure in the setting of bone marrow transplantation. Kidney Int. 1994; 46:1443–1458.
117.
AlessandrinoEP, BernasconiP, CalderaD, . Chemotherapy and donor peripheral blood progenitor cells for acute leukemia in early relapse after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1999; 23:607–612.
118.
SmithDM, WeisenburgerDD, BiermanP, . Acute renal failure associated with autologous bone marrow transplantation. Bone Marrow Transplant. 1987; 2:195–201.
119.
CohenEP. Renal failure after bone-marrow transplantation. Lancet. 2001; 357:6–7.
120.
CohenEP, HussainS, MoulderJE. Successful treatment of radiation nephropathy with angiotensin II blockade. Int J Radiat Oncol Biol Phys. 2003; 55:190–193.
121.
CutlerC, KimHT, HochbergE, . Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2004; 10:328–336.
CohenEP. Radiation nephropathy after bone marrow transplantation. Kidney Int. 2000; 58:903–918.
124.
LiuH, DingJH, LiuBC, . Early renal injury after nonmyeloablative allogeneic peripheral blood stem cell transplantation in patients with chronic myelocytic leukemia. Am J Nephrol. 2007; 27(4):336–341.
125.
CutlerC, StevensonK, KimHT, . Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood. 2008; 12:4425–4431.
126.
EknoyanG. Meeting the challenges of the new K/DOQI guidelines. Am J Kidney Dis. 2003; 41(suppl):3–10.
127.
PalmerBF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med. 2004; 351:585–592.
128.
CohenEP, PieringWF, Kabler-BabbittC, . Endstage renal disease (ESRD) after bone marrow transplantation: poor survival compared to other causes of ESRD. Nephron. 1998; 79:408–412.
129.
ChangJW, TsaiHL, WangHH, . Outcome and risk factors for mortality in children with acute renal failure. Clin Nephrol. 2008; 70:485–489.
130.
LeungAY, MakR, LieAK, . Clinicopathological features and risk factors of clinically overt haemorrhagic cystitis complicating bone marrow transplantation. Bone Marrow Transplant. 2002; 29:509–513.
131.
ComarM, D'AgaroP, AndolinaM, . Hemorrhagic cystitis in children undergoing bone marrow transplantation: a putative role for simian virus. Transplantation. 2004; 78:544–548.
132.
MoriK, YoshiharaT, NishimuraY, . ARF due to adenovirus-associated obstructive uropathy and necrotizing tubulointerstitial nephritis in a bone marrow transplant recipient. Bone Marrow Transplant. 2003; 31:1173–1176.
133.
BenoitDD, DepuydtPO, VandewoudeKH, . Outcome in critically ill medical patients treated with renal replacement therapy for acute renal failure: comparison between patients with and those without haematological malignancies. Nephrol Dial Transplant. 2005; 20:552–558.
